Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3b extension study of subcutaneous vedolizumab in ulcerative colitis and Crohn's disease
MOH_2017-01-05_000040Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of vedolizumab in autoimmune colitis and Crohn's disease (3 arms), sponsored by Takeda. Primary endpoint: Long-term safety and tolerability of subcutaneous vedolizumab. Started Jan 2016; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2017-01-05_000040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-05_000040.